|
|
Disease Modifying Osteoarthritis Drugs - The Search for the 'Holy Grail' ContinuesPublished by: Datamonitor Published: Jan. 1, 2004 - 42 Pages Table of ContentsTABLE OF CONTENTS EXECUTIVE SUMMARY 4 Introduction 4 Scope and coverage of the Brief 4 Key findings about the topic 5 SECTION 1 INTRODUCTION 6 Epidemeology 6 Current treatments available 8 What is required of a DMOAD? 9 Clinical trial design for DMOADs 11 SECTION 2 DMOADS IN THE PIPELINE 19 Preventing cartilage degradation 19 Enhancing cartilage repair 26 Other mechanisms 31 Discontinued trials 34 SECTION 3 COMPARISON OF DMOAD METHODS 36 DMOAD deadlock 36 Comparison of technologies 37 APPENDIX 39 Bibliography 39 AbstractIntroductionOsteoarthritis is a degenerative joint disease occurring mainly in the elderly. It is the most common form of arthritis and Datamonitor estimates that it affects over 73 million people in the seven major pharmaceutical markets. Disease modification is currently the ‘holy grail’ in the treatment of OA, driven by an aging population and recent success of disease modifiers for rheumatoid arthritis. Scope The lack of accuracy and reproducibility of radiography as the method of end-point assessment has created difficulties for clinical trials Research into biomarkers offers a possible solution to both end-point assessment and earlier diagnosis Doxycycline, Amgen’s Kineret and a MMP Inhibitor from P&G offer the most promising DMOAD prospects in the pipeline Success in this area will depend heavily of clinical trial design, dosing regimes and formulation properties of the drug Report Highlights Research is predominantly at an early discovery or pre-clinical stage, with only three products in human trials. P&Gs MMP inhibitor, although at an early stage, has shown promising results in a well-designed trial. Tissue engineering also has great potential as a disease modifying approach, Biosyntech currently have a product, BST-Cargel, in PI. The main issues dominating DMOAD research are, elucidation of the precise mechanism and pathways involved in OA, and selection of the most effective drug delivery approach. Delivery of the drug to the affected joint in a sufficient concentration, without adversely affecting the rest of the body, is proving problematic. The gold standard radiographic method of measuring trial outcome can lack clinical relevance and rarely produces consistently accurate measurements. Symptomatic outcome measurements are subjective and can be influenced by treatments that do not alter the cartilage such as commonly used analgesics and NSAIDs. Reasons to Purchase Understand the current research Compare DMOADs in the pipeline Identify the drivers and constraints in DMOAD research Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||